

Registered Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa-Kharadi Road,
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028.
Email: enquiry@cian.co
Mobile No.: +919049000648 Website: www.cian.co

Corporate Office:

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085.
Landline No.: 011-49120841

Factory: Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,
Roorkee, District Haridwar, Uttarakhand, Pincode-247661.
Mobile No.: +917830655000

CIN: L24233PN2003PLC017563

Ref. No.: CIAN/BSE/2026-27/08

Saturday, May 30, 2026

To,
The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 542678

Trading Symbol: CHCL

Subject: Outcome of the meeting of the Board of Directors of Cian Healthcare Limited held on Saturday, May 30, 2026.

Reference: Intimation dated May 26, 2026, regarding the meeting (CIAN/BM/2026-27/01) of the Board of Directors of Cian Healthcare Limited, scheduled to be held on Saturday, May 30, 2026.

Dear Sir/Madam,


In compliance with the provisions of Regulations 30 and 33, read with Para A of Part A of Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), along with the relevant provisions of SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, and other applicable master circulars, circulars, guidelines, regulations and notifications, as issued by the Securities and Exchange Board of India ("SEBI"), we, Cian Healthcare Limited ("Company"), would like to inform that the Board of the Directors ("Board") of the Company, at their meeting held today i.e. May 30, 2026, which commenced at 02:00 P.M. (IST) and concluded at 03:35 P.M. (IST), *inter-alia* considered the following matters:

1. Approved the Audited Financial Results (Standalone and Consolidated) of the Company for the half year and financial year ended on March 31, 2026, the Statement of Assets & Liabilities as at March 31, 2026 and the Statement of Cash Flows for the financial year ended on March 31, 2026, as recommended by the Audit Committee of the Board ("Financial Results").
2. Noted the Audit Report(s) with modified opinion on the aforesaid Financial Results for the half-year and financial year ended March 31, 2026, issued by M/s S S R C A & Co., Chartered Accountants, Statutory Auditors of the Company.

In this regard and in accordance with the Listing Regulations, please find enclosed herewith the following documents/information:

- a) Financial Results, along with Audit Report(s) thereon for the half year and the financial year ended on March 31, 2026, as **Annexure-A**;





- b) Statement on impact of Audit Qualifications in respect of Audit Report(s) with modified opinions on the aforesaid Financial Results, pursuant to Regulation 33(3)(d) of the Listing Regulations read with the applicable circulars issued by the SEBI, as **Annexure-B**;


The above-stated Financial Results, along with the Statement on the impact of Audit Qualifications in respect of audit reports, for the half-year and financial year ended March 31, 2026, are also being submitted in XBRL mode.

The results and this disclosure will also be accessible on the Company's website at <https://cian.co/>.

Kindly take the above information on record and oblige.

Thanking You
For Cian Healthcare Limited




Rachit Malhotra
Company Secretary and Chief Compliance Officer
Membership No.: A39894

Place: New Delhi

Enclosed: As above

SSRCA & Co.

Chartered Accountants



Independent Auditor's Report on the Audited Standalone Financial Results of Cian Healthcare Limited for the Half Yearly and Year Ended 31st March 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
Cian Healthcare Limited

We have audited the accompanying Statement of Audited Standalone Financial Results of **Cian Healthcare Limited** ('the Company') for the half yearly and year ended 31st March 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

We draw attention to the fact that the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") had admitted the Company into the Corporate Insolvency Resolution Process ("CIRP") vide its order dated 11th June 2024, which was subsequently restored with effect from 14th August 2024. The Resolution Plan submitted by Pradeep Kumar Jain ("the Successful Resolution Applicant / SRA") was approved by the Committee of Creditors ("CoC") with 100% voting share. The Hon'ble NCLT, Mumbai Bench-VI, vide its Order dated 18th December 2025 in IA (I.B.C) (Plan) No. 55/MB/2025 in RST.A (IBC)/52(MB)2024 in C.P.(IB) No. 149/MB/2022, has approved the Resolution Plan submitted by the Successful Resolution Applicant for an amount of Rs. 37,30,13,553/-. Pursuant to the said Order, the moratorium under Section 14 of the Insolvency and Bankruptcy Code, 2016 ceased to have effect, the Resolution Professional stood discharged of his duties, and the management of the affairs of the Company stands vested with the Resolution Plan Implementation Committee / Monitoring Committee, in accordance with the approved Resolution Plan.

This Statement, which is the responsibility of the Company's Management, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our Audit.

We have audited the accompanying annual standalone financial results of Cian Healthcare Limited (hereinafter referred to as "the Company"), for the year ended 31 March 2026 (the "Statement" or "Standalone financial results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

Basis for Qualified Conclusion

Based on our Audit conducted as stated in paragraph 4 above, we draw attention to the following matters which form the basis for our qualified conclusion on the accompanying Statement:

- The balances of trade receivables, advances to others, and deposits paid are subject to confirmation. Due to the non-availability of balance confirmations from the respective parties, we were unable to obtain sufficient appropriate audit evidence regarding the accuracy and completeness of such balances. Consequently, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements for the year ended 31st March 2026.
- In respect of the carrying value of Property, Plant and Equipment and Capital Work-in-Progress as on 31st March 2026, we were unable to obtain the physical verification report and related supporting documents. Consequently, in the absence of sufficient and appropriate audit evidence, we are unable to comment on the carrying value of such assets and the consequential impact, if any, on the accompanying financial statements as at and for the year ended 31 March 2026.
- The inventory revaluation exercise was carried out on 18th December 2025 by the Resolution Professional (RP) during the Corporate Insolvency Resolution Process (CIRP). Based on such exercise, the value of inventory was determined at INR 603.10 lakhs as against the carrying value of INR 1,956.90 lakhs reflected in the books of account, resulting in a difference of INR 1,353.73 lakhs. The said valuation and related financial



SSRCA & Co.

Chartered Accountants



information were prepared and submitted by the Resolution Professional. Accordingly, such difference has a material impact on the valuation of closing inventory and cost of goods sold. In the absence of sufficient appropriate audit evidence to support the inventory value recorded by the management, we are unable to determine the consequential impact, if any, on the accompanying standalone financial statements.

- An amount of ₹347.28 lakhs has been written off by the management and disclosed under Exceptional Gain/Loss on the ground of difference in GST ITC between Books of accounts and ITC shown on GST portal. However, proper GST reconciliation and supporting documentation in respect of the same have not been provided for our verification. Accordingly, we are unable to comment on the GST balances reported in the accompanying standalone financial statements.
- The Foreign Exchange Gain/Loss has not been computed on a transaction-wise basis as generally required under the applicable accounting framework; instead, the computation has been performed only based on year-end closing balances. Such methodology is not in accordance with generally accepted accounting principles. In the absence of transaction-wise computation, supporting reconciliations, we are unable to comment on the correctness and completeness of the Foreign Exchange Gain/Loss reported in the financial statements as at and for the year ended 31 March 2026
- During the course of audit, we observed that the Company has recognized an Expected Credit Loss (ECL) provision amounting to INR 2,916.74 lakhs in respect of long outstanding loans and advances, trade receivables/debtors, and advances given to suppliers, considering that such balances are either not recoverable, are significantly aged, or confirmations/responses have not been received. However, we have not been provided with sufficient and appropriate audit evidence supporting the basis, and methodology adopted for determination of such provision, including ageing analysis, recovery assessment, supporting correspondence, and management evaluation of recoverability
- The Company has been taken over by the current management pursuant to an Order of the Hon'ble National Company Law Tribunal (NCLT) under the Insolvency and Bankruptcy Code, 2016. The management is in the process of assuming control of the business and undertaking an evaluation of the existing systems, processes, and internal controls. During the course of our audit, the Company did not make available to us documentation pertaining to **Internal Financial Controls over Financial Reporting (IFCFR)**. Consequently, we were unable to obtain sufficient appropriate audit evidence to assess whether adequate internal financial controls over financial reporting had been established and whether such controls were operating effectively as at 31st March 2026.
- The company has represented that it maintains an audit trail as required under the applicable provisions of the Companies Act, 2013. However, we were unable to independently verify the integrity, completeness, and effectiveness of the audit trail for the year under audit. Accordingly, we are unable to comment on the adequacy and operating effectiveness of the audit trail maintained by the company.
- Section 129(3) of Companies Act 2013, mandates that companies with subsidiaries or associate companies must prepare consolidated financial statements, in addition to their standalone financial statements. We draw attention to Note 8 of the accompanying standalone financial results, which describes the circumstances relating to the investment of ₹708.84 lakhs made by the Company in its subsidiary, Dr. Smiths Biotech Private Limited. However, as the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") admitted an Insolvency and Bankruptcy petition filed by a financial creditor against Dr. Smiths Biotech Private Limited ("the subsidiary") and ordered the commencement of Corporate Insolvency Resolution Process (CIRP) of Dr. Smiths Biotech Private Limited, the Company/Corporate Debtor, vide its Order dated 28th April 2025 and Megha Agrawal (IBBI/IPA-001/IP-P-01456/2018- 2019/12272) is appointed as the Interim Resolution Professional by, the NCLT and subsequently appointed as Resolution Professional. As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs and written off the balance amount of INR 488.84 lakhs, representing securities premium, through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.



Qualified Conclusion

Based on our Audit conducted as stated above, except for the possible effects of the matters described in the Basis for Qualified Conclusion section of our report, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Results

This standalone financial result has been prepared on the basis of standalone financial results. The Company's management is responsible for the preparation and presentation of the standalone financial results that give a true and fair view of the net loss and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone financial results, the management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors, either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The management are also responsible for overseeing the Company's financial reporting process read together with Note 1 of the standalone financial results.

Auditor's Responsibility for the Audit of the Annual Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.

SSRCA & Co. Chartered Accountants



Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation

Emphasis of Matters

We draw attention to Note no 1 and "Basis of preparation and presentation" section of Note 2 to the standalone financial statement which describes the admission of Corporate Insolvency Resolution Process ("CIRP") application led by an operational creditor of the company by an order of the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai Bench-VI with effect from 14th August 2024.

Pradeep Kumar Jain, the successful resolution applicant has infused the required investments as per the approved Resolution Plan and these financial results have been prepared after giving effect to the said Resolution Plan and based on the confirmation of the settlement of financial and operating creditors as approved by the RP. Pursuant to the implementation of the Said Plan, the Company became a subsidiary of M/s Ananta Medicare Limited.

We draw attention to **Note no 2** to the standalone financial statement which describes the implementation of the resolution plan pursuant to approval by National Company Law Tribunal and the resultant impacts of the same on the financial results for the year ended 31st March, 2026.

Our conclusion is not modified in respect of above matters.

For SSRCA & Co.

Chartered Accountants

(Formerly known as S S Rathi & Co.)

Firm's Registration No. 108726W



CA Hemant Samdani

Partner

Membership No. 155955

UDIN: 26155955KPJXSG6084

Place: Pune

Date: 30 May 2026

CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT-01 KONARK CON, 3RD FLOOR, 1N-114, CC NO-4979, HN-10/1, NR. MAGARPAITA, Hadapsar, Pune - 411028 | www.cian.co | +91 9049233757 | enquiry@cian.co

Statement of Audited Standalone Financial Results for the Half Year and Year Ended 31st March 2026 (Standalone)

(Amount in ₹ Lakhs unless otherwise stated)

Sl.	Particulars	Half Year Ended 01 Oct 2025 to 31 Mar 2026 (Audited)	Half Year Ended 01 Apr 2025 to 31 Sep 2025 (Unaudited)	Half Year Ended 01 Oct 2024 to 31 Mar 2025 (Audited)	Year Ended 31 Mar 2026 (Audited)	Year Ended 31 Mar 2025 (Audited)
I INCOME FROM CONTINUING OPERATIONS						
	Income from Operations	1,697.68	1,132.17	1,233.54	2,829.85	1,088.23
	Other Income	53.17	62.82	18.88	115.99	25.27
	Total Income	1,750.85	1,194.99	1,252.42	2,945.84	1,113.50
II EXPENSES						
	Cost of Materials Consumed	739.94	926.06	929.06	1,666.00	1,858.28
	Purchases of Trading Goods	2.60	20.37	64.37	22.97	147.67
	Changes in Inventories of Finished Goods & Work-in-Progress	470.28	93.50	(46.31)	563.78	33.21
	Other Operating Expenses	204.46	109.53	126.84	313.99	334.39
	Employee Benefits Expenses	365.13	222.95	287.34	588.08	645.04
	Finance Costs	20.64	0.33	6.20	20.97	203.96
	Depreciation and Amortisation Expense	106.68	106.32	106.36	212.99	260.61
	Other Expenses	191.08	127.01	173.72	318.09	362.39
	Total Expenses	2,100.81	1,608.07	1,647.58	3,706.87	3,855.55
	III PROFIT / (LOSS) BEFORE EXCEPTIONAL ITEMS AND TAX (I - II)	(349.96)	(413.08)	(395.16)	(761.03)	(742.05)
IV EXCEPTIONAL ITEMS						
	Exceptional Items (Net)	1,329.37	0.43	20.25	1,329.80	1,225.37
	V PROFIT / (LOSS) BEFORE TAX (III ± IV)	(1,679.33)	(412.65)	(415.41)	(2,090.82)	(1,967.42)
VI TAX EXPENSE						
	(a) Current Tax (MAT)	0.00	0.00	0.00	0.00	0.00
	(b) Tax Relating to Prior Years	0.00	0.00	(3.87)	0.00	(3.87)
	(c) Deferred Tax	3.84	7.37	2.09	11.21	2.10
	Total Tax Expense	3.84	7.37	(1.78)	11.21	(1.77)
	VII NET PROFIT / (LOSS) AFTER TAX (V - VI)	(1,683.17)	(420.02)	(413.63)	(2,102.03)	(1,965.85)
VIII OTHER COMPREHENSIVE INCOME						
	a. (i) Items not reclassified to P&L (net of tax)	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items not reclassified	0.00	0.00	0.00	0.00	0.00
	b. (i) Items that may be reclassified to P&L (net of tax)	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that may be reclassified	0.00	0.00	0.00	0.00	0.00
IX PAID-UP EQUITY SHARE CAPITAL (Face Value ₹ 10/- per share)						
	Paid-Up Equity Share Capital	2,500.00	2,499.58	2,499.58	2,500.00	2,499.58
X OTHER EQUITY						
	Other Equity (Reserves and Surplus)					
XI EARNINGS PER SHARE (Before Exceptional Items)						
	Basic (₹)	(1.42)	(1.67)	(1.57)	(3.09)	(2.96)
	Diluted (₹)	(1.42)	(1.67)	(1.57)	(3.09)	(2.96)
XII EARNINGS PER SHARE (After Exceptional Items)						
	Basic (₹)	(6.73)	(1.68)	(1.65)	(8.41)	(7.86)
	Diluted (₹)	(6.73)	(1.68)	(1.65)	(8.41)	(7.86)

See accompanying notes to the audited financial results

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563

Rajesh Jain
RAJESH JAIN

Managing Director

DIN: 02066848

Date: 30 May 2026

Place: Pune



CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT 01 SONARWALON, 3RD FLOOR, 5th-134, CC NO-4979, HN-10/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 | www.cian.co | +91 9049233757 | enquiry@cian.co

Audited Standalone Statement of Assets and Liabilities as at 31st March 2026 [Standalone]

As at 31st March 2026 | (Amount in ₹ Lakhs unless otherwise stated)

Particulars	31 Mar 2026 (Audited)	31 Mar 2025 (Audited)
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
Share Capital	2,500.00	2,499.58
Reserves and Surplus	(439.41)	1,715.94
Sub-Total - Shareholders' Funds	2,060.59	4,215.52
2. Non-Current Liabilities		
Long-Term Borrowings	1,366.96	37.48
Deferred Tax Liabilities (Net)	104.52	93.31
Other Long-Term Liabilities	0.56	85.05
Long-Term Provisions	285.08	76.70
Sub-Total - Non-Current Liabilities	1,757.12	292.54
3. Current Liabilities		
Short-Term Borrowings	0.00	3,961.92
Trade Payables		
(a) Total Outstanding Dues - MSME	45.28	733.61
(b) Total Outstanding Dues - Others	348.87	2,653.68
Other Current Liabilities	566.32	2,321.08
Short-Term Provisions	43.87	89.16
Sub-Total - Current Liabilities	1,004.34	9,759.44
TOTAL EQUITY AND LIABILITIES	4,822.06	14,267.50
B ASSETS		
1. Non-Current Assets		
Property, Plant and Equipment & Intangible Assets		
(i) Tangible Assets	2,200.56	2,331.65
(ii) Intangible Assets	0.00	0.00
(iii) Capital Work-in-Progress	615.74	1,506.60
Non-Current Investments	220.00	708.84
Long-Term Loans and Advances	0.00	1,198.04
Other Non-Current Assets	46.91	1,825.17
Sub-Total - Non-Current Assets	3,083.22	7,570.30
2. Current Assets		
Inventories	459.48	2,562.11
Trade Receivables	912.08	1,554.42
Cash and Cash Equivalents	112.94	1,765.65
Short-Term Loans and Advances	11.15	417.56
Other Current Assets	243.19	397.47
Sub-Total - Current Assets	1,738.84	6,697.20
TOTAL ASSETS	4,822.06	14,267.50

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563

Rajesh Jain


RAJESH JAIN

Managing Director

DIN: 02066848

Date : 30 May 2026

Place : Pune



CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT-01 KONARK ICON, 3RD FLOOR, SN-134, CC NO-4979, HN-10/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 |

www.cian.co | +91 9049233757 | enquiry@cian.co

Audited Standalone Statement of Cash Flows for the Year Ended 31st March 2026 [Standalone]

(Amount in ₹ Lakhs unless otherwise stated)

Particulars	Year Ended 31 March 2026 (Audited)	Year Ended 31 March 2025 (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit / (Loss) After Tax	(2,102.03)	(1,965.65)
Adjustments for Non-Cash / Non-Operating Items:		
Depreciation and Amortisation	212.99	260.61
Interest Expenses	18.98	163.14
Less: Interest on Fixed Deposits	(38.23)	(13.81)
Deferred Tax Expense / (Benefit)	11.21	2.10
Exceptional Items – Non-Cash Charges (Net)	1,329.80	0.00
Exceptional Gain / (Loss) – Non-Operating	2,198.13	0.00
Operating Profit Before Working Capital Changes	1,830.85	(1,553.61)
Movements in Working Capital:		
Increase/(Decrease) in Trade Payables	(2,993.13)	873.30
Increase/(Decrease) in Other Current Liabilities	(1,754.76)	1,850.65
Increase/(Decrease) in Other Non-Current Liabilities	(84.49)	(685.26)
Increase/(Decrease) in Provisions (LT & ST)	163.09	4.61
(Increase)/Decrease in Inventories	2,102.63	1,205.77
(Increase)/Decrease in Trade Receivables	642.35	275.99
(Increase)/Decrease in Other Current Assets	194.27	(41.54)
(Increase)/Decrease in Other Non-Current Assets	1,778.26	104.15
(Increase)/Decrease in Short-Term Loans and Advances	406.41	31.57
A. Net Cash Generated From / (Used In) Operating Activities	2,045.47	2,065.63
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of PPE / Intangibles	(82.05)	(3.88)
(Increase)/Decrease in Capital Work-in-Progress	890.86	(36.68)
Interest on Fixed Deposits Received	38.23	13.81
(Increase)/Decrease in Non-Current Investments	488.84	0.00
B. Net Cash Generated From / (Used In) Investing Activities	1,335.88	(26.74)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issuance of Equity Share Capital	0.42	0.00
Proceeds/(Repayment) of Long-Term Borrowings	1,329.48	(1,491.12)
Proceeds/(Repayment) of Short-Term Borrowings	(3,961.92)	1,389.64
(Increase)/Decrease in Long-Term Loans and Advances	1,196.04	(81.36)
Interest Paid	(18.98)	(163.14)
Securities Premium Utilised for Capital Reduction (Non-Cash)	(3,561.11)	0.00
C. Net Cash Generated From / (Used In) Financing Activities	(5,034.06)	(345.97)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	(1,852.70)	1,692.92
Cash and Cash Equivalents – Opening Balance	1,765.65	72.73
Cash and Cash Equivalents – Closing Balance	112.94	1,765.65



CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT 01 KOWARK ICON, 3RD FLOOR, SN-134, CC NO-4979, IIN-1D/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 |

www.cian.co | +91 9049233737 | enquiry@cian.co

Audited Standalone Statement of Cash Flows for the Year Ended 31st March 2026 (Standalone)

(Amount in ₹ Lakhs unless otherwise stated)

Particulars	Year Ended	Year Ended
	31 March 2026 (Audited)	31 March 2025 (Audited)
Components of Closing Cash Balance		
Cash in Hand	0.11	0.40
With Banks - Current Account	86.15	1,006.93
With Banks - Fixed Deposit Account	25.68	758.23
Cash and Cash Equivalents as per Balance Sheet	112.94	1,765.56

Note: Cash Flow Statement is prepared under the Indirect Method in accordance with AS 3 (Cash Flow Statements).

See accompanying notes to the audited financial results

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563

Rajesh Jain


RAJESH JAIN

Managing Director

DIN: 0206848

Date: 30 May 2026

Place: Pune



Notes to the Statement of Audited Standalone Financial Results for the year ended 31st March 2026
Corporate Information

The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") had admitted an Insolvency and Bankruptcy petition filed by a operational creditor against Cian Healthcare Limited ("the Company") and ordered the commencement of Corporate Insolvency Resolution Process ("CIRP") vide its Order dated 11th June 2024 in C.P.(IB) No. 149/MB/2022, which was subsequently restored with effect from 14th August 2024. Roshen Chordiya was appointed as the Interim Resolution Professional and was subsequently confirmed as the Resolution Professional ("RP") by the Committee of Creditors ("COC").

The Resolution Plan submitted by Pradeep Kumar Jain ("the Successful Resolution Applicant" / "SRA") was approved by the Committee of Creditors unanimously with 100% voting share. The Hon'ble NCLT, Mumbai Bench-VI, vide its Order dated 18th December 2025 in IA (I.B.C.)-(Plan) No. 55/MB/2025 in RST.A (IBC)/52(MB)2024 in C.P. (IB) No. 149/MB/2022, has approved the Resolution Plan submitted by the Successful Resolution Applicant for an amount of Rs. 37,30,13,553/-

Basis of preparation of financial statements

- These financial results have been prepared after giving effect to the said Resolution Plan and based on the confirmation of the settlement of financial and operating creditors as approved by the RP. Pursuant to the implementation of the Said Plan, the Company became a subsidiary of Anata Medicare Limited. In view of the implementation of the Said Plan, the standalone financial statements have been prepared and presented by the Company on a Going Concern basis.
- Pursuant to NCLT Order dated 18th December, 2025, which was implemented from 1st February 2026 (i.e. closing date as defined under the resolution plan) otherwise as stated in below notes, the following consequential impacts have been given in accordance with approved resolution plan / Accounting Standards:-

- **Summary of Claims received and admitted during CIRP**

In response to the public announcements made during the CIRP, the RP received total claims aggregating to INR 8,147.07 lakhs, comprising claims from secured financial creditors, unsecured financial creditors, operational creditors (Government dues, workmen, employees, and others), and other creditors. The total admitted claims stood at INR 7,449.63/- lacs. The distribution under the approved Resolution Plan has been carried out in accordance with the directions of the NCLT.

- **Capital Reserve arising from Implementation of Resolution Plan**

Pursuant to the approval and implementation of the Resolution Plan by the Hon'ble NCLT vide Order dated 18th December 2025, payments to creditors have been made in accordance with the Resolution Plan as follows:

The balance debt of the Financial Creditors, Operational Creditors and/or other creditors, remaining unpaid after making payments as per the Resolution Plan, has been dealt with in accordance with the applicable accounting standards. As per the ICAI Guidance on accounting for Resolution Plan implementation, any gain arising from the extinguishment of liabilities under the approved Resolution Plan has been credited to Capital Reserve and not to the Statement of Profit and Loss, in accordance with the Resolution Plan as approved by the NCLT. This Capital Reserve is not distributable and forms part of the other equity of the Company.

Particulars	Amount (Rs.)
(A) Total Admitted Claims (all creditor classes, including CIRP costs as admitted)	74,49,63,965
(B) Less: Total Bid Value (amount proposed to be paid under the Resolution Plan as approved by NCLT)	(37,30,13,553)
(C) Capital Reserve [= (A) – (B)]	37,19,50,412



- The existing issued, subscribed and paid-up equity share capital of the Company has been reduced from INR 2,374.58 lakhs of equity share and securities premium INR 3,581.11 lakhs total of Rs.5,955.69 lakh divided into 2,49,95,764 equity share of INR 10.00 each per share. As prescribed in the Resolution Plan, the reduction in the share capital of the Company amounting to INR 2,374.58 lakhs and INR 3,581.11 lakhs is adjusted against the Capital Reduction and Capital Reserve respectively.

- Capital Restructuring and Introduction of Fresh Capital**

Pursuant to the NCLT Order dated 18th December 2025 approving the Resolution Plan, the existing equity share capital of the Company stood cancelled in its entirety. Thereafter, fresh equity shares have been issued as per the capital structure envisaged in the Resolution Plan through SRA and its nominee affiliates, resulting in a revised paid-up share capital of **Rs. 25,00,00,000/-** (Rupees Twenty-Five Crores) divided into 2,50,00,000 equity shares of Rs. 10/- each. The shareholding post-implementation is as under:

Sr. No.	Name of Shareholder	Amount (Rs.)	% Holding
1	Pradeep Kumar Jain (SRA)	4,75,00,000	19.00%
2	Rajesh Jain	5,25,00,000	21.00%
3	Ananta Medicare Limited	13,75,00,000	55.00%
4	Public Shareholders	1,25,00,000	5.00%
	Total	25,00,00,000	100.00%

As per Rule 19A(5) of the Securities Contracts (Regulation) Rules, 1957, the Company shall maintain a minimum public shareholding of 5% of the expanded equity as a result of implementation of the Resolution Plan by continuing listing on BSE Limited. The Successful Resolution Applicant (SRA) has undertaken in the resolution plan to increase the public shareholding from (5%) to at least 10% within 12 Months and 25% within stipulated time of 03 years from NCLT approval date as per the SEBI Act Rules and Regulations.

- Unsecured Loans**

Pursuant to the NCLT Order dated 18th December 2025 and the approved Resolution Plan, the Successful Resolution Applicant and its nominee affiliates have extended unsecured loans to the Company for working capital requirements and operational purposes. The details of unsecured loans outstanding as at 31st March 2026 are as under:

Sr. No.	Name of Lender	Amount (Rs.)
1	Pradeep Kumar Jain (SRA)	4,20,00,000.00
2	Rajesh Jain	2,55,67,500.00
3	Ananta Medicare Limited	6,69,62,500.00
	Total	13,55,30,000.00

These loans are unsecured, repayable in fully on or before the last day of the Loan Term, i.e., at the end of two years from the Date of Disbursement. The loan amount carry interest at rate of 7.3% p.a on simple interest basis.



- Out of funds received amounting to INR 3730.13 lakhs is to be used for settlement of claims as mentioned below:

Category of Creditor	Amount Claimed (Rs.)	Amount Admitted (Rs.)	Amount Paid as approved in NCLT Order	Amount Paid / Treatment
CIRP Cost	-	2,00,00,000	2,20,00,000	
Secured Financial Creditors (Assenting)	32,66,83,190.23	32,66,83,190.23	32,66,83,190	Paid at 100% of admitted claims
Unsecured Financial Creditors (Assenting – unrelated)	2,49,521.00	2,49,521.00	2,49,521.00	Paid at 100% of admitted claims
Operational Creditors – Workmen & Employees	51,91,076.00	51,91,076.00	51,91,076.00	Paid at 100% of admitted claims
Operational Creditors – Govt. Dues	5,59,81,740.00	5,53,09,082.00	24,55,723.00	Paid @ 4.415% of admitted claims
Operational Creditors (Other)	34,87,38,518.00	26,55,97,448.31	1,17,92,527.00	Paid @ 4.415% of admitted claims
Other Creditors	29,252.73	29,252.73	29,252.73	Paid at 100% of admitted claims
Contingency Fund			8613.00	
Total	81,02,06,592	74,49,63,965	37,30,13,553	

- **Exceptional items (Related to Balance Sheet) for year ended as on 31st March 2026 comprises of :**
 1. Deferred Revenue Expenditure of Rs. 1,670.25 lakhs has been written off by the RP, as Revenue Expenditure is to be charged to P & L account in the year of incurrence and deferment is not allowed under Indian GAAP
 2. Write-off of Capital Work-in-Progress amounting to INR 892.47 lakhs and related interest expenses due to the non-availability of corresponding CWIP, products/items on which R&D activities were undertaken, and corresponding products at the site.
 3. Provision have been made of Non-current assets of INR 1475.28 /- and Current assets of INR 1305.53 lakhs related to, trade receivables/debtors, and advances given to suppliers, considering that such balances are either not recoverable, are significantly aged, or confirmations/responses have not been received.
 4. GST Balance amounting to INR 347.28 lakhs has been written off by the RP in the handing over financials to the current management as credit was being carried forwards
 5. Write-off of Sitting fees, salary, bonus, and TDS and Income tax refund amounting to INR 27.84 lakhs;
 6. Provision for trade deposits and trade payables amounting to INR 684.23 lakhs in respect of parties who had not lodged their claims with the Resolution Professional (RP).
 7. Provision of Investment in subsidiaries of 220.00 lakhs related to Dr. Smith's Biotech Private Limited,
 8. Write off of Investment in subsidiaries of 488.84 lakhs related to Dr. Smith's Biotech Private Limited.
- **Exceptional items (Related to Profit & Loss) for year ended as on 31st March 2026 comprises of :-**



1. Inventory revaluation exercise carried out by the RP, and the value of inventory has been devalued by 1353.73 lakhs upon the restatement of the non –moving, slow moving and damaged items at net realisable value.
2. Write-off of sundry debtor balances amounting to INR 23.93 lakhs.

These adjustments have arisen pursuant to the NCLT Order and have had a one-time, non-routine material impact on the financial results; accordingly, the same have been disclosed as "Exceptional Items" in the Financial Results..

- The current management (SRA) has taken over the affairs of the company on 1st February 2026 and is the process of seeking balance confirmations of Receivables/ Advance from Customers/ Suppliers and adjustment if any would be booked. The management is of the opinion that it would not have significant difference in the carrying value of the same. Provisions has already been made for the doubtful assets, the adjustments, if any, would not have a material impact on the profitability of the company.
- **Approval of Financial Results:** The above Financial Statement and Statement of Assets and Liabilities have been prepared as per applicable Accounting Standards and have been reviewed and taken on record at the meeting of the Board of Directors held on 30 May 2026. The statutory auditors have expressed a Qualified Opinion in respect of the standalone financial statement for the year ended 31st March 2026.
- The Earnings per Share (EPS) has been computed in accordance with Accounting Standard AS-20 'Earnings Per Share'.
- **List of Subsidiary**

Name of the Entity	Dr. Smith's Biotech Private Limited
Relationship	Wholly owned Subsidiary
Country of Incorporation	India
% of Ownership	100%

- **Status of Investor Complaints**

The status of Investor Complaints during the year ended 31st March 2026 is as under:

Pending at the beginning of the period	NIL
Received during the period	NIL
Disposed during the period	NIL
Remaining unresolved at the end of the period	NIL

- **Investment in Subsidiary – CIRP of Dr. Smith's Biotech Private Limited**

The Company has an investment in its wholly-owned subsidiary, Dr. Smith's Biotech Private Limited, amounting to Rs. 708.84 Lakhs. The Hon'ble National Company Law Tribunal, Mumbai Bench, admitted an Insolvency and Bankruptcy petition filed by a financial creditor against Dr. Smith's Biotech Private Limited and ordered the commencement of CIRP of the said subsidiary vide its Order dated 28th April 2025, and Megha Agrawal (IBBI/IPA-001/IP-P-01456/2018-2019/12272) was appointed as the Resolution Professional.

As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs, and written off the balance amount of INR 488.84 lakhs, representing securities premium, through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.

- **Regrouping / Reclassification**

Figures for the previous year / period have been regrouped / reclassified wherever necessary, to make them comparable with the current year presentation.



- **Segment Reporting**

The Company is primarily engaged in the business of Pharmaceuticals, which constitutes a single reportable segment for the year ended 31st March 2026. Accordingly, no separate segment reporting is required as per AS-17 'Segment Reporting'.

- **Applicability of Indian Accounting Standards (Ind AS)**

As per MCA Notification dated 16th February 2015, companies whose shares are listed on an SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the mandatory requirement of adoption of Ind AS. Accordingly, the Company has prepared its financial results as per the Accounting Standards notified under Section 133 of the Companies Act, 2013.

For and on behalf of the Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563



Rajesh Jain

Rajesh Jain

Managing Director

DIN: 02066848

Place: Pune

Date: 30 May 2026

Independent Auditor's Report on the Consolidated Financial Results of Cian Healthcare Limited for the Half Yearly and Year Ended 31st March 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
Cian Healthcare Limited

We have audited the accompanying Statement of Audited Consolidated Financial Results of **Cian Healthcare Limited** ('the Holding Company') and Dr. Smith's Biotech Private Limited ('the Subsidiary Company') for the half yearly and year ended 31st March 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

The Consolidated Financial Statements for the year ended 31st March 2026 includes the financial statements of holding company **Cian Healthcare Limited** and subsidiary company **Dr. Smith's Biotech Private Limited** for the year ended 31st March 2026.

The standalone financial statements of Dr. Smith's Biotech Private Limited (the Subsidiary) for the year ended 31st March 2026 have been audited by another auditor. However, the audit report contains a Disclaimer of Opinion, which has been furnished to us, and we have relied upon the same for the purpose of consolidation. Accordingly, we do not express any opinion on the completeness and true and fair view of financial statements including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries for the year ended 31st March 2026 included in the Consolidated Financial Statements.

In case of Holding Company, we draw your attention to the facts that the Hon'ble National Company Law Tribunal, Mumbai Bench-("NCLT") had admitted Company into the Corporate Insolvency Resolution Process ("CIRP") vide its order dated 11th June 2024, which was subsequently restored with effect from 14th August 2024. The Resolution Plan submitted by Pradeep Kumar Jain ("the Successful Resolution Applicant / SRA") was approved by the Committee of Creditors ("CoC") with 100% voting share. The Hon'ble NCLT, Mumbai Bench-VI, vide its Order dated 18th December 2025 in IA (I.B.C) (Plan) No. 55/MB/2025 in RST.A (IBC)/52(MB)2024 in C.P.(IB) No. 149/MB/2022, has approved the Resolution Plan submitted by the Successful Resolution Applicant for an amount of Rs. 37,30,13,553/-.

In case of subsidiary Company, we draw attention to the fact that the Hon'ble NCLT, Mumbai Bench admitted an insolvency and bankruptcy petition filed by a financial creditor against **Dr. Smith's Biotech Private Limited** ("the Subsidiary"), a wholly-owned subsidiary of the Company, vide its Order dated **28th April 2025**, ordering the commencement of CIRP of the Subsidiary. **Megha Agrawal** (IBBI/IPA-001/IP-P-01456/2018-2019/12272) has been appointed as the Interim Resolution Professional / Resolution Professional of the Subsidiary. The Subsidiary's operations have remained entirely halted since August 2024 due to financial distress.

The Consolidated annual financial results includes the financial results of the following entities:

Holding Company Cian Healthcare Limited

Subsidiary Company Dr. Smith's Biotech Private Limited

Basis for Qualified Conclusion

We draw attention to the following matters pertaining to the Holding Company – Cian Healthcare Limited:

- The balances of trade receivables, advances to others, and deposits paid are subject to confirmation. Due to the non-availability of balance confirmations from the respective parties, we were unable to obtain sufficient appropriate audit evidence regarding the accuracy and completeness of such balances. Consequently, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements for the year ended 31st March 2026.

SSRCA & Co.

Chartered Accountants



- In respect of the carrying value of Property, Plant and Equipment and Capital Work-in-Progress as on 31st March 2026, we were unable to obtain the physical verification report and related supporting documents. Consequently, in the absence of sufficient and appropriate audit evidence, we are unable to comment on the carrying value of such assets and the consequential impact, if any, on the accompanying consolidated financial statements.
- The inventory revaluation exercise was carried out on 18th December 2025 by the Resolution Professional (RP) during the Corporate Insolvency Resolution Process (CIRP). Based on such exercise, the value of inventory was determined at INR 603.10 lakhs as against the carrying value of INR 1,956.90 lakhs reflected in the books of account, resulting in a difference of INR 1,353.73 lakhs. The said valuation and related financial information were prepared and submitted by the Resolution Professional. Accordingly, such difference has a material impact on the valuation of closing inventory and cost of goods sold. In the absence of sufficient appropriate audit evidence to support the inventory value recorded by the management, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements.
- The amount of ₹347.28 lakhs has been written off by the management and disclosed under Exceptional Gain/Loss on the ground that the corresponding input tax credit was not available on the GST portal. However, proper GST reconciliation and supporting documentation in respect of the same have not been provided for our verification. Accordingly, we are unable to comment on the GST balances reported in the accompanying consolidated financial statements.
- The Foreign Exchange Gain/Loss has not been computed on a transaction-wise basis; instead, the computation has been performed only on the basis of year-end closing balances. Such methodology is not in accordance with generally accepted accounting principles. We are unable to comment on the correctness and completeness of the Foreign Exchange Gain/Loss reported.
- During the course of Audit, we observed that the Company has recognised an Expected Credit Loss (ECL) provision amounting to INR 2,916.74 lakhs in respect of long outstanding loans and advances, trade receivables/debtors, and advances given to suppliers. However, we have not been provided with sufficient and appropriate audit evidence supporting the basis and methodology adopted for determination of such provision, including ageing analysis, recovery assessment, supporting correspondence, and management evaluation of recoverability.
- The Company has been taken over by the current management pursuant to an Order of the Hon'ble National Company Law Tribunal (NCLT) under the Insolvency and Bankruptcy Code, 2016. The management is in the process of assuming control of the business and undertaking an evaluation of the existing systems, processes, and internal controls. During the course of our audit, the Company did not make available to us documentation pertaining to **Internal Financial Controls over Financial Reporting (IFCFR)**. Consequently, we were unable to obtain sufficient appropriate audit evidence to assess whether adequate internal financial controls over financial reporting had been established and whether such controls were operating effectively as at 31st March 2026.
- The company has represented that it maintains an audit trail as required under the applicable provisions of the Companies Act, 2013. However, we were unable to independently verify the integrity, completeness, and effectiveness of the audit trail for the year under audit. Accordingly, we are unable to comment on the adequacy and operating effectiveness of the audit trail maintained by the company.
- The Company has represented that it maintains an audit trail as required under the applicable provisions of the Companies Act, 2013. However, we were unable to independently verify the integrity, completeness, and effectiveness of the audit trail for the year under audit.

Section 129(3) of the Companies Act, 2013 mandates that companies with subsidiaries must prepare consolidated financial statements. We draw attention to **Note 8** of the accompanying consolidated financial results, which describes the investment of ₹708.84 lakhs made by the Company in its wholly-owned subsidiary, Dr. Smiths Biotech Private Limited. The Subsidiary is currently undergoing CIRP under the Insolvency and Bankruptcy Code, 2016, vide NCLT order dated 28th April 2025. The Subsidiary's operations have remained entirely halted since August 2024. As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs and written off the balance amount of INR 488.84 lakhs, representing



SSRCA & Co.

Chartered Accountants



securities premium, through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.

• Subsidiary's Financial Results – Dr. Smith's Biotech Private Limited

*The Statement includes the financial results of Dr. Smith's Biotech Private Limited, a subsidiary, whose financial statements for the year ended 31st March 2026 reflect Total Assets of Rs. 1,682.40 Lakhs, Total Liabilities of Rs. 2,669.39 Lakhs, Net Worth of Rs. (987.00) Lakhs, and Total Revenue of Rs. 1.03 Lakhs. The financial statements of this subsidiary for the year ended 31st March 2026 were audited by another auditor and the audit report contained a **Disclaimer of Opinion**, which has been furnished to us and relied upon for the purpose of consolidation.*

Basis for Disclaimer of Opinion of Subsidiary's Auditor:

The Disclaimer of Opinion on the Subsidiary's financial statements was issued primarily on account of the following:

- The Subsidiary has halted its business operations since August 2024 due to financial distress and is currently undergoing CIRP under the IBC, 2016. In the absence of any concrete resolution plan and given that operations have ceased, there exists a significant uncertainty regarding the Subsidiary's ability to continue as a going concern. The financial statements have been prepared on a going concern basis based on representations received from the Resolution Professional.
- Whilst the Resolution Professional represented that a physical verification of fixed assets was conducted during the year, no physical verification reports, supporting documentation, or reconciliation with the books of accounts were made available. In the absence of such evidence, the subsidiary's auditor was unable to comment on the existence, physical condition, and valuation of fixed assets carrying a book value of ₹983.00 Lakhs as of 31st March 2026, or any potential adjustments / impairments required therein.
- The Resolution Professional informed the auditor that there is no change in inventory levels and no obsolescence has occurred. However, in the absence of a physical inventory counting report or independent verification records as at year-end, the subsidiary's auditor was unable to comment on the existence, condition, and valuation of inventories valued at ₹45.46 Lakhs in the financial statements.
- No direct balance confirmations or independent reconciliations were provided for Trade Receivables amounting to ₹415.99 Lakhs and Trade Payables / Creditors amounting to ₹1,014.21 Lakhs. In the absence of alternative audit procedures due to the ongoing insolvency proceedings, the subsidiary's auditor was unable to determine whether any adjustments are necessary regarding these balances. Further, no provisioning or write-offs have been considered by the management / RP for potentially doubtful debts, pending finalisation of the Resolution Plan.
- The Subsidiary has defaulted in the timely deposition and payment of undisputed statutory dues, including GST, TDS, PF, ESIC, etc., with the appropriate authorities.
- The books of accounts reflect an ITC balance of ₹103.64 Lakhs as on 31st March 2026. However, as per the GST portal, the available ITC balance was only ₹22.34 Lakhs, resulting in an unreconciled difference of ₹81.3 Lakhs. In the absence of reconciliations and adequate explanations, the subsidiary's auditor was unable to comment on the correctness of the ITC balance shown in the books of accounts.
- The management did not provide details about audit trail logs maintained in the accounting software. The subsidiary's auditor was accordingly unable to comment on whether the audit trail (edit log) facility was in operation throughout the year, whether the audit trail feature was tampered with, or whether the records were retained for the prescribed period.

Material Uncertainty Related to Going Concern – Subsidiary:

The subsidiary's auditor drew attention to Note No. 1(i) of the Subsidiary's financial statements, which indicates that the Subsidiary is currently undergoing CIRP under the IBC, 2016, and its operations have remained entirely halted throughout the year. These conditions, along with the defaults in statutory dues, indicate the existence of a material uncertainty that may cast significant doubt on the Subsidiary's ability to continue as a going concern. However, during the year, a successful investor was selected and has deposited a performance guarantee with the lenders.



The Subsidiary's financial statements have been prepared on a going concern basis for the reasons stated in the said note.

Accordingly, our conclusion on the consolidated Statement is not modified in respect of the Subsidiary's financial results and the above matters.

Qualified Conclusion

Based on our audit conducted as stated above, except for the possible effects of the matters described in the Basis for Qualified Conclusion section of our report, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Results

This Statement has been prepared on the basis of consolidated financial results. The Company's Management is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit / (loss) and other financial information of the Group in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, read

with relevant rules issued thereunder, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors are responsible for maintenance of adequate accounting records; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls.

In preparing the Consolidated Financial Results, the Board of Directors is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. we also:

- a) Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error; design and perform audit procedures responsive to those risks; and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of respective management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

Emphasis of Matters

We draw attention to Note No. 1 and the "Basis of Preparation and Presentation" section of Note 2 to the consolidated financial statement which describes the admission of the CIRP by an order of the Hon'ble NCLT, Mumbai Bench-VI with effect from 14th August 2024, and its subsequent conclusion pursuant to the NCLT Order dated 18th December 2025 approving the Resolution Plan

Pradeep Kumar Jain, the Successful Resolution Applicant, has infused the required investments as per the approved Resolution Plan and these financial results have been prepared after giving effect to the said Resolution Plan and based on the confirmation of the settlement of financial and operating creditors as approved by the RP. Pursuant to the implementation of the said Plan, the Company has become a subsidiary of M/s Ananta Medicare Limited.

Emphasis of Matter – Subsidiary:

The subsidiary's auditor drew attention to the fact that the Corporate Insolvency Resolution Process (CIRP) in respect of the Subsidiary was initiated under the IBC, 2016. Consequently, the powers of the Board of Directors stand suspended and the management and operations of the Subsidiary are being overseen and managed by the Resolution Professional, Megha Agrawal.

We draw attention to Note No. 2 to the consolidated financial statement which describes the implementation of the Resolution Plan pursuant to approval by the Hon'ble NCLT and the resultant impacts of the same on the consolidated financial results for the year ended 31st March 2026.

We further draw attention to paragraph 4 and the Subsidiary's Financial Results section of this report regarding the ongoing CIRP of the wholly-owned subsidiary, Dr. Smith's Biotech Private Limited, vide NCLT Order dated 28th April 2025, and the Disclaimer of Opinion issued by the Subsidiary's another auditor.

Our conclusion is not modified in respect of the above matters.

SSRCA & Co. Chartered Accountants



Other Matter


The consolidated financial results include the financial results of the Subsidiary, Dr. Smith's Biotech Private Limited, for the year ended 31st March 2026, whose financial statements were audited by another auditor. The said auditor issued a **Disclaimer of Opinion** on the Subsidiary's financial statements for the year ended 31st March 2026. Our conclusion on the consolidated Statement, in so far as it relates to the amounts and disclosures included in respect of the Subsidiary, is based solely on the report of the Subsidiary's statutory auditor. We have not independently audited or reviewed the Subsidiary's financial statements.

For SSRCA & Co.

Chartered Accountants

(Formerly known as S S Rathi & Co.)

Firm's Registration No. 108726W



CA Hemant Samdani

Partner

Membership No. 155955

UDIN: 26155955 UYDWLU7844

Place: Pune

Date: 30 May 2026

CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT-01 KONARK (CON. 3RD FLOOR, SH. 134, CC NO-4979, HN-10/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 | www.cian.co | +91 9049211757 | enquiry@cian.co

Statement of Audited Consolidated Financial Results for the Half Year and Year Ended 31st March 2026 [Consolidated]

(Amount in ₹ Lakhs unless otherwise stated)


Sr.	Particulars	Half Year Ended 01 Oct 2025 to 31 Mar 2026 (Audited)	Half Year Ended 01 Apr 2025 to 30 Sep 2025 (Unaudited)	Half Year Ended 01 Oct 2024 to 31 Mar 2025 (Audited)	Year Ended 31 Mar 2026 (Audited)	Year Ended 31 Mar 2025 (Audited)
I INCOME FROM CONTINUING OPERATIONS						
	Income from Operations	1,697.68	1,132.17	1,190.30	2,829.85	3,079.84
	Other Income	54.20	62.82	19.92	117.07	28.82
	Total Income	1,751.88	1,194.99	1,210.22	2,946.92	3,108.66
II EXPENSES						
	Cost of Materials Consumed	739.94	928.06	22.46	1,666.00	922.65
	Purchases of Trading Goods	2.60	20.37	205.12	22.97	407.60
	Changes in Inventories of Finished Goods & Work-in-Progress	470.28	93.50	856.50	563.78	938.11
	Other Operating Expenses	204.46	109.53	91.13	313.99	334.39
	Employee Benefits Expenses	365.13	222.95	295.14	588.06	700.62
	Finance Costs	20.63	0.81	50.83	21.44	291.54
	Depreciation and Amortisation Expense	195.69	195.81	195.63	391.50	439.12
	Other Expenses	217.05	150.32	247.87	367.37	446.79
	Total Expenses	2,318.78	1,719.85	1,964.48	3,935.15	4,480.82
	III PROFIT / (LOSS) BEFORE EXCEPTIONAL ITEMS AND TAX (I - II)	(463.90)	(524.86)	(754.26)	(988.23)	(1,372.16)
IV EXCEPTIONAL ITEMS						
	Exceptional Items (Net)	1,329.37	0.43	20.25	1,329.80	1,225.37
	V PROFIT / (LOSS) BEFORE TAX (III + IV)	(1,795.27)	(524.79)	(774.51)	(2,318.06)	(2,599.53)
VI TAX EXPENSE						
	(a) Current Tax (MAT)	0.00	0.00	0.00	0.00	0.00
	(b) Tax Relating to Prior Years	0.00	0.00	(3.87)	0.00	(3.87)
	(c) Deferred Tax	3.84	7.37	2.09	11.21	2.10
	Total Tax Expense	3.84	7.37	(1.78)	11.21	(1.77)
	VII NET PROFIT / (LOSS) AFTER TAX (V - VI)	(1,799.11)	(532.16)	(772.73)	(2,329.27)	(2,597.75)
VIII OTHER COMPREHENSIVE INCOME						
a.	(i) Items not reclassified to P&L (net of tax)	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items not reclassified	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that may be reclassified to P&L (net of tax)	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that may be reclassified	0.00	0.00	0.00	0.00	0.00
IX PAID-UP EQUITY SHARE CAPITAL (Face Value ₹ 10/- per share)						
	Paid-Up Equity Share Capital	2,500.00	2,499.58	2,499.58	2,500.00	2,499.58
X OTHER EQUITY						
	Other Equity (Reserves and Surplus)					
XI EARNINGS PER SHARE (Before Exceptional Items)						
	Basic (₹)	(1.87)	(2.13)	(3.01)	(4.00)	(5.49)
	Diluted (₹)	(1.87)	(2.13)	(3.01)	(4.00)	(5.49)
XII EARNINGS PER SHARE (After Exceptional Items)						
	Basic (₹)	(7.19)	(2.13)	(3.09)	(9.32)	(10.39)
	Diluted (₹)	(7.19)	(2.13)	(3.09)	(9.32)	(10.39)

See accompanying notes to the audited financial results

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563



Rajesh Jain
RAJESH JAIN

Managing Director

DIN: 02068848

Date: 30 May 2026

Place: Pune

CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLCO17563

UNIT-01 KONAARK ICON, 3RD FLOOR, SN-134, CC NO-4979, HN-1D/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 | www.cian.co | +91 9049233757 | enquiry@cian.co

Statement of Consolidated Assets and Liabilities as at 31st March 2026 (Consolidated)


As at 31st March 2026 / (Amount in ₹ Lakhs unless otherwise stated)

Particulars	31 Mar 2026 (Audited)	31 Mar 2025 (Audited)
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
Share Capital	2,500.00	2,499.58
Reserves and Surplus	(1,646.41)	736.15
Sub-Total - Shareholders' Funds	853.59	3,235.73
2. Non-Current Liabilities		
Long-Term Borrowings	2,015.92	685.79
Deferred Tax Liabilities (Net)	64.32	53.12
Other Long-Term Liabilities	21.12	105.61
Long-Term Provisions	285.08	76.70
Sub-Total - Non-Current Liabilities	2,386.44	921.22
3. Current Liabilities		
Short-Term Borrowings	849.94	4,812.96
Trade Payables		
(a) Total Outstanding Dues - MSME	639.60	1,416.83
(b) Total Outstanding Dues - Others	712.09	2,750.74
Other Current Liabilities	649.68	2,361.81
Short-Term Provisions	64.03	106.56
Sub-Total - Current Liabilities	2,915.35	11,448.90
TOTAL EQUITY AND LIABILITIES	6,155.38	15,605.85
B ASSETS		
1. Non-Current Assets		
Property, Plant and Equipment & Intangible Assets		
(i) Tangible Assets	3,183.56	3,493.16
(ii) Intangible Assets	0.00	0.00
(iii) Capital Work-in-Progress	615.74	1,506.60
Non-Current Investments	10.32	488.84
Long-Term Loans and Advances	0.00	1,198.04
Other Non-Current Assets	57.85	1,835.52
Sub-Total - Non-Current Assets	3,867.48	8,922.15
2. Current Assets		
Inventories	504.94	2,607.57
Trade Receivables	1,264.26	1,739.10
Cash and Cash Equivalents	119.62	1,777.04
Short-Term Loans and Advances	43.36	532.34
Other Current Assets	355.72	427.65
Sub-Total - Current Assets	2,287.91	7,083.70
TOTAL ASSETS	6,155.38	15,605.85

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLCO17563



Rajesh Jain

RAJESH JAIN

Managing Director

DIN: 02066848

Date : 30 May 2026

Place : Pune

CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLCD17563

UNIT-01 KONARK ICDM, 3RD FLOOR, SN-134, CC NO-4979, HN-1D/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 |

www.cian.co | +91 9049233757 | enquiry@cian.co

Statement of Consolidated Cash Flows for the Year Ended 31st March 2026 [Consolidated]

(Amount in ₹ Lakhs unless otherwise stated)

Particulars	Year Ended 31 March 2026 (Audited)	Year Ended 31 March 2025 (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit / (Loss) After Tax	(2,329.27)	(2,597.75)
Adjustments for Non-Cash / Non-Operating Items:		
Depreciation and Amortisation	391.50	439.12
Interest Expenses	19.43	250.60
Less: Interest on Fixed Deposits	(39.25)	(15.14)
Deferred Tax Expense / (Benefit)	11.21	2.10
Exceptional Items - Non-Cash Charges (Net)	1,329.80	0.00
Exceptional Gain / (Loss) - Non-Operating	2,198.13	0.00
Operating Profit Before Working Capital Changes	1,581.55	(1,921.08)
Movements in Working Capital:		
Increase/(Decrease) in Trade Payables	(2,815.88)	1,040.45
Increase/(Decrease) in Other Current Liabilities	(1,712.13)	1,757.12
Increase/(Decrease) in Other Non-Current Liabilities	(84.49)	(664.70)
Increase/(Decrease) in Provisions (LT & ST)	165.86	21.41
(Increase)/Decrease in Inventories	2,102.63	1,485.16
(Increase)/Decrease in Trade Receivables	474.84	309.17
(Increase)/Decrease in Other Current Assets	71.93	(71.72)
(Increase)/Decrease in Other Non-Current Assets	1,777.67	93.80
(Increase)/Decrease in Short-Term Loans and Advances	488.98	25.60
A. Net Cash Generated From / (Used In) Operating Activities	2,050.96	2,075.20
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of PPE / Intangibles	(81.91)	(3.88)
(Increase)/Decrease in Capital Work-in-Progress	890.86	(36.68)
Interest on Fixed Deposits Received	39.25	15.14
(Increase)/Decrease in Non-Current Investments	478.52	0.00
B. Net Cash Generated From / (Used In) Investing Activities	1,326.72	(25.42)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issuance of Equity Share Capital	0.42	0.00
Proceeds/(Repayment) of Long-Term Borrowings	1,330.13	(2,063.83)
Proceeds/(Repayment) of Short-Term Borrowings	(3,963.03)	1,993.45
(Increase)/Decrease in Long-Term Loans and Advances	1,198.04	(71.17)
Interest Paid	(19.43)	(250.60)
Securities Premium Utilised for Capital Reduction (Non-Cash)	(3,581.11)	0.00
C. Net Cash Generated From / (Used In) Financing Activities	(5,034.97)	(392.15)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	(1,657.29)	1,657.63
Cash and Cash Equivalents - Opening Balance	1,777.04	119.41
Cash and Cash Equivalents - Closing Balance	119.75	1,777.04



CIAN HEALTHCARE LIMITED

CIN: L24233PN2003PLC017563

UNIT-01 KONARK ICON, 3RD FLOOR, SH-134, CC NO-4979, HN-10/2, NR. MAGARPATTA, Hadapsar, Pune - 411028 |
www.cian.co | +91 9049283757 | enquiry@cian.co

Statement of Consolidated Cash Flows for the Year Ended 31st March 2026 (Consolidated)

(Amount in ₹ Lakhs unless otherwise stated)

Particulars	Year Ended	Year Ended
	31 March 2026 (Audited)	31 March 2025 (Audited)
Components of Closing Cash Balance		
Cash in Hand	0.18	0.49
With Banks - Current Account	92.89	1,008.00
With Banks - Fixed Deposit Account	26.68	768.55
Cash and Cash Equivalents as per Balance Sheet	119.75	1,777.04

Note: Cash Flow Statement is prepared under the Indirect Method in accordance with AS 3 (Cash Flow Statements).

For and on behalf of Board of Directors

Cian Healthcare Limited

CIN: L24233PN2003PLC017563

RAJESH JAIN

Managing Director

DIN: 02066848

Date: 30 May 2026

Place: Pune



Notes to the Statement of Audited Consolidated Financial Results for the year ended 31st March 2026

Corporate Information

The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") had admitted an Insolvency and Bankruptcy petition filed by a operational creditor against Cian Healthcare Limited ("the Company") and ordered the commencement of Corporate Insolvency Resolution Process ("CIRP") vide its Order dated 11th June 2024 in C.P.(IB) No. 149/MB/2022, which was subsequently restored with effect from 14th August 2024. Roshen Chordiya was appointed as the Interim Resolution Professional and was subsequently confirmed as the Resolution Professional ("RP") by the Committee of Creditors ("COC").

The Resolution Plan submitted by Pradeep Kumar Jain ("the Successful Resolution Applicant" / "SRA") was approved by the Committee of Creditors unanimously with 100% voting share. The Hon'ble NCLT, Mumbai Bench-VI, vide its Order dated 18th December 2025 in IA (I.B.C.) (Plan) No. 55/MB/2025 in RST.A (IBC)/52(MB)2024 in C.P.(IB) No. 149/MB/2022, has approved the Resolution Plan submitted by the Successful Resolution Applicant for an amount of Rs. 37,30,13,553/-.

Basis of preparation of financial statements

- These financial results have been prepared after giving effect to the said Resolution Plan and based on the confirmation of the settlement of financial and operating creditors as approved by the RP. Pursuant to the implementation of the Said Plan, the Company became a subsidiary of Anata Medicare Limited. In view of the implementation of the Said Plan, the consolidated financial statements have been prepared and presented by the Company on a Going Concern basis.
- Pursuant to NCLT Order dated 18th December, 2025, which was implemented from 1st February 2026 (i.e. closing date as defined under the resolution plan) otherwise as stated in below notes, the following consequential impacts have been given in accordance with approved resolution plan / Accounting Standards :-

- **Summary of Claims received and admitted during CIRP**

In response to the public announcements made during the CIRP, the RP received total claims aggregating to INR 8,147.07 lakhs, comprising claims from secured financial creditors, unsecured financial creditors, operational creditors (Government dues, workmen, employees, and others), and other creditors. The total admitted claims stood at INR 7,449.63/-Lakhs. The distribution under the approved Resolution Plan has been carried out in accordance with the directions of the NCLT.

- **Capital Reserve arising from Implementation of Resolution Plan**

Pursuant to the approval and implementation of the Resolution Plan by the Hon'ble NCLT vide Order dated 18th December 2025, payments to creditors have been made in accordance with the Resolution Plan as follows:

The balance debt of the Financial Creditors, Operational Creditors and/or other creditors, remaining unpaid after making payments as per the Resolution Plan, has been dealt with in accordance with the applicable accounting standards. As per the ICAI Guidance on accounting for Resolution Plan implementation, any gain arising from the extinguishment of liabilities under the approved Resolution Plan has been credited to Capital Reserve and not to the Statement of Profit and Loss, in accordance with the Resolution Plan as approved by the NCLT. This Capital Reserve is not distributable and forms part of the other equity of the Company.

Particulars	Amount (Rs.)
(A) Total Admitted Claims (all creditor classes, including CIRP costs as admitted)	74,49,63,965
(B) Less: Total Bid Value (amount proposed to be paid under the Resolution Plan as approved by NCLT)	(37,30,13,553)
(C) Capital Reserve [= (A) - (B)]	37,19,50,412



1. The existing issued, subscribed and paid-up equity share capital of the Company has been reduced from INR 2,374.58 lakhs of equity share and securities premium INR 3,581.11 lakhs total of Rs.5,955.69 lakh divided into 2,49,95,764 equity share of INR 10.00 each per share. As prescribed in the Resolution Plan, the reduction in the share capital of the Company amounting to INR 2,374.58 lakhs and INR 3,581.11 lakhs is adjusted against the Capital Reduction and Capital Reserve respectively.

2. **Capital Restructuring and Introduction of Fresh Capital**

3. Pursuant to the NCLT Order dated 18th December 2025 approving the Resolution Plan, the existing equity share capital of the Company stood cancelled in its entirety. Thereafter, fresh equity shares have been issued as per the capital structure envisaged in the Resolution Plan through SRA and its nominee affiliates, resulting in a revised paid-up share capital of **Rs. 25,00,00,000/-** (Rupees Twenty-Five Crores) divided into 2,50,00,000 equity shares of Rs. 10/- each. The shareholding post-implementation is as under:

Sr. No.	Name of Shareholder	Amount (Rs.)	% Holding
1	Pradeep Kumar Jain (SRA)	4,75,00,000	19.00%
2	Rajesh Jain	5,25,00,000	21.00%
3	Ananta Medicare Limited	13,75,00,000	55.00%
4	Public Shareholders	1,25,00,000	5.00%
	Total	25,00,00,000	100.00%

As per Rule 19A(5) of the Securities Contracts (Regulation) Rules, 1957, the Company shall maintain a minimum public shareholding of 5% of the expanded equity as a result of implementation of the Resolution Plan by continuing listing on BSE Limited. The Successful Resolution Applicant (SRA) has undertaken in the resolution plan to increase the public shareholding from (5%) to at least 10% within 12 Months and 25% within stipulated time of 03 years from NCLT approval date as per the SEBI Act Rules and Regulations.

4. **Unsecured Loans**

Pursuant to the NCLT Order dated 18th December 2025 and the approved Resolution Plan, the Successful Resolution Applicant and its nominee affiliates have extended unsecured loans to the Company for working capital requirements and operational purposes. The details of unsecured loans outstanding as at 31st March 2026 are as under:

Sr. No.	Name of Lender	Amount (Rs.)
1	Pradeep Kumar Jain (SRA)	4,30,00,000.00
2	Rajesh Jain	2,55,67,500.00
3	Ananta Medicare Limited	6,69,62,500.00
	Total	13,55,30,000.00

These loans are unsecured, repayable in fully on or before the last day of the Loan Term, i.e., at the end of two years from the Date of Disbursement. The loan amount carry interest at rate of 7.3% p.a on simple interest basis.



5. Out of funds received amounting to INR 3730.13 lakhs is to be used for settlement of claims as mentioned below:

Category of Creditor	Amount Claimed (Rs.)	Amount Admitted (Rs.)	Amount Paid as approved in NCLT Order	Amount Paid / Treatment
CIRP Cost	-	2,00,00,000	2,20,00,000	
Secured Financial Creditors (Assenting)	32,66,83,190.23	32,66,83,190.23	32,66,83,190	Paid at 100% of admitted claims
Unsecured Financial Creditors (Assenting – unrelated)	2,49,521.00	2,49,521.00	2,49,521.00	Paid at 100% of admitted claims
Operational Creditors – Workmen & Employees	51,91,076.00	51,91,076.00	51,91,076.00	Paid at 100% of admitted claims
Operational Creditors – Govt. Dues	5,59,81,740.00	5,53,09,082.00	24,55,723.00	Paid @ 4.415% of admitted claims
Operational Creditors (Other)	34,87,38,518.00	26,55,97,448.31	1,17,92,527.00	Paid @ 4.415% of admitted claims
Other Creditors	29,252.73	29,252.73	29,252.73	Paid at 100% of admitted claims
Contingency Fund			8613.00	
Total	81,02,06,592	74,49,63,965	37,30,13,553	

6. **Exceptional items (Related to Balance Sheet) for year ended as on 31st March 2026 comprises of :**
9. Deferred Revenue Expenditure of Rs. 1,670.25 lakhs has been written off by the RP, as Revenue Expenditure is to be charged to P & L account in the year of incurrence and deferment is not allowed under Indian GAAP
 10. Write-off of Capital Work-in-Progress amounting to INR 892.47 lakhs and related interest expenses due to the non-availability of corresponding CWIP, products/items on which R&D activities were undertaken, and corresponding products at the site.
 11. Provision have been made of Non-current assets of INR 1475.28 /- and Current assets of INR 1305.53 lakhs related to, trade receivables/debtors, and advances given to suppliers, considering that such balances are either not recoverable, are significantly aged, or confirmations/responses have not been received.
 12. GST Balance amounting to INR 347.28 lakhs has been written off on the ground that the corresponding input tax credit was not available on the GST portal.
 13. Write-off of Sitting fees, salary, bonus, and TDS and Income tax refund amounting to INR 27.84 lakhs;
 14. Write-off of trade deposits, trade payables amounting to INR 684.23 lakhs;
 15. Provision of Investment in subsidiaries of 220.00 lakhs related to Dr. Smith's Biotech Private Limited,
 16. Write off of Investment in subsidiaries of 488.84 lakhs related to Dr. Smith's Biotech Private Limited.
7. **Exceptional items (Related to Profit & Loss) for year ended as on 31st March 2026 comprises of :-**
8. Inventory revaluation exercise carried out, and the value of inventory has been revalued to 1353.73 pertaining previous financial year.



9. Write-off of sundry debtor balances amounting to INR 23.93 lakhs.

These adjustments, having one-time, non-routine material impact on the financial results hence the same has been disclosed as "Exceptional Items" in the Financial Results.

- Third party balance confirmation in case of trade receivables, advance from customers, advance to suppliers, has not been received and significantly balance outstanding as on 31st March 2026 cannot be stated.
- **Approval of Financial Results:** The above Financial Statement and Statement of Assets and Liabilities have been prepared as per applicable Accounting Standards and have been reviewed and taken on record at the meeting of the Board of Directors held on 30 May 2026. The statutory auditors have expressed a Qualified Opinion in respect of the consolidated financial statement for the year ended 31st March 2026.
- The Earnings per Share (EPS) has been computed in accordance with Accounting Standard AS-20 'Earnings Per Share'.

- **List of Subsidiary**

Name of the Entity	Dr. Smith's Biotech Private Limited
Relationship	Wholly owned Subsidiary
Country of Incorporation	India
% of Ownership	100%

- **Status of Investor Complaints**

The status of Investor Complaints during the year ended 31st March 2026 is as under:

Pending at the beginning of the period	NIL
Received during the period	NIL
Disposed during the period	NIL
Remaining unresolved at the end of the period	NIL

- **Investment in Subsidiary – CIRP of Dr. Smith's Biotech Private Limited**

The Company has an investment in its wholly-owned subsidiary, Dr. Smith's Biotech Private Limited, amounting to Rs. 708.84 Lakhs. The Hon'ble National Company Law Tribunal, Mumbai Bench, admitted an Insolvency and Bankruptcy petition filed by a financial creditor against Dr. Smith's Biotech Private Limited and ordered the commencement of CIRP of the said subsidiary vide its Order dated 28th April 2025, and Megha Agrawal (IBBI/PA-001/IP-P-01456/2018-2019/12272) was appointed as the Resolution Professional.

As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs, and written off the balance amount of INR 488.84 lakhs, representing securities premium, through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.

- **Regrouping / Reclassification**

Figures for the previous year / period have been regrouped / reclassified wherever necessary, to make them comparable with the current year presentation.



- **Segment Reporting**

The Company is primarily engaged in the business of Pharmaceuticals, which constitutes a single reportable segment for the year ended 31st March 2026. Accordingly, no separate segment reporting is required as per AS-17 'Segment Reporting'.

- **Applicability of Indian Accounting Standards (Ind AS)**

As per MCA Notification dated 16th February 2015, companies whose shares are listed on an SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the mandatory requirement of adoption of Ind AS. Accordingly, the Company has prepared its financial results as per the Accounting Standards notified under Section 133 of the Companies Act, 2013.

For and on behalf of the Board of Directors

Clan Healthcare Limited

CIN: L24233PN2003PLC017563



Rajesh Jain

Rajesh Jain

Managing Director


DIN: 02066848

Place: Pune


Date: 30 May 2026.

Statement of Impact of Audit Qualifications (for audit report with modified opinion) submitted along with Annual Audited Financial Results – Standalone				
Statement of Impact of Audit Qualifications for the Financial Year ended 31st March 2026 (See Regulation 33 of SEBI (LODR) Regulations, 2015)				
I	Sl. No.	Particulars	Audited Figures (Rs. in Lakhs) (as reported before adjusting for qualifications)	Audited Figures (Rs. in Lakhs) (as reported after adjusting for qualifications)
	1	Turnover / Total Income	2,945.84	2,945.84
	2	Total Expenditure	3,706.86	5,036.66
	3	Net Profit / (Loss) after tax	(772.23)	(2,102.03)
	4	Earnings Per Share (Rs.)	(3.09)	(8.41)
	5	Total Assets	4,822.06	4,822.06
	6	Total Liabilities	2,761.47	2,761.47
	7	Net Worth	2060.59	2060.59


II. Audit Qualifications – Details and Management Response (Standalone)	
(a) Type of Audit Qualification: Qualified Opinion	
(b) Frequency of Qualification: First year - Qualified Opinion (Previous year: Disclaimer of Opinion)	
Qualification as reported in the Auditor's Report	Management's Views / Response
(c) Qualification where impact is QUANTIFIED by the Auditor:	
<p>(c-i) Inventory Valuation – Difference between Book Value and Revalued Value:</p> <p>The inventory revaluation exercise was carried out on 18th December 2025 by the Resolution Professional (RP) during the Corporate Insolvency Resolution Process (CIRP). Based on such exercise, the value of inventory was determined at INR 603.10 lakhs as against the carrying value of INR 1,956.90 lakhs reflected in the books of account, resulting in a difference of INR 1,353.73 lakhs. The said valuation and related financial information were prepared and submitted by the Resolution Professional. Accordingly, such difference has a material impact on the valuation of closing inventory and cost of goods sold. In the absence of sufficient appropriate audit evidence to support the inventory value recorded by the management, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements.</p> <p>Quantified Impact: ↑ Expenditure / Cost of Goods Sold by Rs. 1,353.73 lakhs; ↓ Inventory (Assets) by Rs. 1,353.73 lakhs; ↓ Net Profit by Rs. 1,353.73 lakhs.</p>	<p>Management's Response:</p> <p>The Resolution Professional has devalued the inventory by Rs. 1,353.73 lakhs upon the restatement of the non-moving, slow moving & damaged items at Net Realisable Value/ Scrap Value and has incorporated the same in the handling over financials to the implementation committee formed under the NCLT order for implementing resolution plan.</p> <p>The current management is in the process of incorporating the devaluation as above in the inventory module of the ERP Software, considering the large number of line items in the inventory, it is taking considerable time. Further the management is also evaluating the updated ERP Software for deployment.</p> <p>The management is of the view that the inventories are valued at cost or net realisable value, whichever is lower, in accordance with applicable Accounting Standards.</p>




II. Audit Qualifications – Details and Management Response (Standalone)	
(d) Qualifications where impact is NOT QUANTIFIED by the Auditor:	
(d)(i) Management's estimation on the impact of audit qualifications: Nil – Management is unable to estimate the financial impact at this stage for the following qualifications.	
(d)(ii) If Management is unable to estimate the impact, reasons for the same:	
<p>(d-i) Trade Receivables, Advances and Deposits – Balance Confirmations Not Received:</p> <p>The balances of trade receivables, advances to others, and deposits paid are subject to confirmation. Due to non-availability of balance confirmations from the respective parties, we are unable to obtain sufficient appropriate audit evidence. Hence, we are unable to determine whether there is any consequential impact, if any, on the accompanying financial statements for the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>The current management (SRA) has taken over the affairs of the company on 1st February 2026 and is the process of seeking balance confirmations of Receivables/ Advance from Customers/ Suppliers and adjustment if any would be booked. The management is of the opinion that it would not have significant difference in the carrying value of the same. Provisions has already been made for the doubtful assets, the adjustments, if any, would not have a material impact on the profitability of the company.</p>
<p>(d-ii) Property, Plant and Equipment and Capital Work-in-Progress – Physical Verification Not Obtained:</p> <p>In respect of the carrying value of Property, Plant and Equipment and Capital Work-in-Progress as on 31st March 2026, we were unable to obtain the physical verification report and related supporting documents. Consequently, in the absence of sufficient and appropriate audit evidence, we are unable to comment on the carrying value of such assets and the consequential impact, if any, on the accompanying financial statements as at and for the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>For the purposes of handing over a true and fair statement of affairs of the Company to the SRA, the RP conducted a comprehensive physical verification and evaluation of the non-current and current assets of the company was undertaken after the NCLT order the same has been shared with the Auditors.</p> <p>The current management is in the process of implementing a system of physical verification, commensurate with the size of the company, in compliance with the provisions of Companies Act 2013.</p>
<p>(d-iii) GST Balance – Reconciliation Not Provided:</p> <p>The amount of ₹347.28 lakhs has been written off by the management and disclosed under Exceptional Gain/Loss on the ground of difference in GST ITC between Books of accounts and ITC shown on GST portal. However, proper GST reconciliation and supporting documentation in respect of the same have not been provided for our verification. Accordingly, we are unable to comment on the GST balances reported in the accompanying standalone financial statements.</p>	<p>Management's Response:</p> <p>Write –off of Rs 347.28 lakhs has been done by the RP which was also recorded in the handing over financials to the Implementation committee.</p> <p>Regarding the differences in the current period which are mainly because of timing differences in return filing, Goods in Transit etc. There is a time gap in recording of GST purchases as all material received at the plant is accepted and purchase recorded after QC. Some continuing vendors are yet to record the NCLT mandated haircut in their books which is creating the reconciliation difference.</p>




II. Audit Qualifications – Details and Management Response (Standalone)	
<p>(d-iv) Foreign Exchange Gain/Loss:</p> <p>The Foreign Exchange Gain/Loss has not been computed on a transaction-wise basis as generally required under the applicable accounting framework; instead, the computation has been performed only on the basis of year-end closing balances. Such methodology is not in accordance with generally accepted accounting principles. In the absence of transaction-wise computation and supporting reconciliations, we are unable to comment on the correctness and completeness of the Foreign Exchange Gain/Loss reported in the financial statements as at and for the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>Pursuant to NCLT Order dated 18th December, 2025, which was implemented from 1st February 2026 (i.e. closing date as defined under the resolution plan). It was difficult to analyse and reconcile the differences of prior periods.</p> <p>We will perform the reconciliation in the subsequent reporting period</p>
<p>(d-v) Expected Credit Loss (ECL) Provision – Basis Not Supported:</p> <p>During the course of audit, we observed that the Company has recognised an Expected Credit Loss (ECL) provision amounting to INR 2,780.81 lakhs in respect of long outstanding loans and advances, trade receivables/debtors, and advances given to suppliers, considering that such balances are either not recoverable, are significantly aged, or confirmations/responses have not been received. However, we have not been provided with sufficient and appropriate audit evidence supporting the basis and methodology adopted for determination of such provision, including ageing analysis, recovery assessment, supporting correspondence, and management evaluation of recoverability.</p>	<p>Management's Response:</p> <p>For the purposes of handing over a true and fair statement of affairs of the Company to the SRA, the RP conducted a comprehensive physical verification and evaluation of the non-current and current assets of the company was undertaken after the NCLT order the same has been shared with the Auditors.</p> <p>The note regarding the same has been included in the handing over notes by the RP, which have been shared with the auditor.</p> <p>The management is of the opinion that it would not have significant difference in the carrying value of the same. Provisions has already been made for the doubtful assets, the adjustments would not have a material impact on the future profitability of the company.</p>
<p>(d-vi) Internal Financial Controls Over Financial Reporting – Not Made Available:</p> <p>The system of Internal Financial Controls over financial reporting was not made available to us to determine whether the Company has established adequate internal financial controls over financial reporting and whether such internal financial controls were operating effectively during the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>The current management is in the process of evaluation of the IFC Structure borrowed by the erstwhile management and establishing adequate internal financial controls over financial reporting to ensure the operating effectiveness of internal financial controls commensurate to the size of the company.</p> <p>Further, the management is also evaluating the updated ERP Software for deployment to avoid such deviations in the future.</p>
<p>(d-vii) Audit Trail – Unable to Verify:</p> <p>The Company has represented that it maintains an audit trail as required under the applicable provisions of the Companies Act, 2013. However, we were unable to independently verify the integrity, completeness, and effectiveness of the audit trail for the year under. Accordingly, we are unable to comment on the adequacy</p>	<p>Management's Response:</p> <p>The ERP Software in use has the facility of maintaining audit logs and edit trail, the same was shown to the audit team during the course of the audit. Further, the management is also evaluating the updated</p>



II. Audit Qualifications – Details and Management Response (Standalone)	
<p>and operating effectiveness of the audit trail maintained by the Company.</p>	<p>ERP Software for deployment to avoid such deviations in the future.</p>
<p>(d-viii) Investment in Subsidiary – Dr. Smiths Biotech Private Limited (CIRP in Progress):</p> <p>Section 129(3) of the Companies Act, 2013 mandates that companies with subsidiaries must prepare consolidated financial statements. We draw attention to Note 8 of the accompanying standalone financial results, which describes the circumstances relating to the investment of ₹708.84 lakhs made by the Company in its subsidiary, Dr. Smiths Biotech Private Limited. The Hon'ble NCLT, Mumbai Bench admitted an Insolvency and Bankruptcy petition against Dr. Smiths Biotech Private Limited vide its Order dated 28th April 2025 and Megha Agrawal (IBBI/PA-001/IP-P-01456/2018-2019/12272) has been appointed as the Interim Resolution Professional / Resolution Professional. As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs and written off the balance amount of INR 488.84 lakhs, representing securities premium, through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.</p>	<p>Management's Response:</p> <p>Share Premium of Rs. 488.84 lakhs, relating to Investment in subsidiary company has been written off and the investment of Rs. 220.00 lakhs being its face value has been provided for by the RP as the company is under CIRP process. The final accounting treatment would be done after the NCLT pronounces its order on Dr. Smith. However, since the investment has been fully provided for, there would be no impact on the profitability of the company.</p> <p>The facts have already been disclosed in Note 8 of notes to accounts</p>
<p>(d)(ix) Auditor's comment on (i) and (ii) above: Auditor's comments are self-explanatory as stated in the Auditor's Report issued for the half-year and year ended 31st March 2026.</p>	



<p>For and on behalf of the Board of Directors Cian Healthcare Limited CIN: L24233PN2003PLC017563</p> <p><i>Rajesh Jain</i></p> <p>Rajesh Jain Managing Director DIN: 02066848</p> <p>Date: 30/05/2026 Place: Pune</p>	<p>Statutory Auditors For S S R C A & Co. Chartered Accountants (Formerly known as S S Rathl & Co.) Firm Registration No. 108726W</p> <p><i>Hamant Samdani</i></p> <p>CA Hamant Samdani Partner Membership No. 155955 UDIN: <u>26155955 KPIX SG6084</u> Date: 30/05/2026 Place: Pune</p> 
<p>For and on behalf of the Audit Committee Chairman Cian Healthcare Limited CIN: L24233PN2003PLC017563</p> <p><i>Manish Goswami</i></p> <p>Manish Goswami Director DIN: 05301935</p> <p>Date: 30/05/2026 Place: Pune</p>	<p>For and on behalf of the Cian Healthcare Limited CIN: L24233PN2003PLC017563</p> <p><i>Kalyani Ghordia</i></p> <p>Kalyani Vajay Ghordia CFO</p> <p>Date: 30/05/2026 Place: Pune</p>




Statement of Impact of Audit Qualifications (for audit report with modified opinion) submitted along with Annual Audited Consolidated Financial Results – Cian Healthcare Limited				
Statement of Impact of Audit Qualifications for the Financial Year ended 31st March 2026 [See Regulation 33 of SEBI (LODR) Regulations, 2015]				
I	Sl. No.	Particulars	Audited Figures (Rs. in Lakhs) (as reported before adjusting for qualifications)	Audited Figures (Rs. in Lakhs) (as reported after adjusting for qualifications)
	1	Turnover / Total Income	2,946.87	2,946.87
	2	Total Expenditure	(5,288.86)	(3,935.13)
	3	Net Profit / (Loss) after tax	(999.47)	(2,329.27)
	4	Earnings Per Share (Rs.)	(4.00)	(9.32)
	5	Total Assets	6,155.38	6,155.38
	6	Total Liabilities	5,301.79	5,301.79
	7	Net Worth	853.59	853.59
Note on Consolidated Figures:				

II. Audit Qualifications – Details and Management Response (Consolidated)	
(a) Type of Audit Qualification: Qualified Opinion	
(b) Frequency of Qualification: First year – Qualified Opinion on Consolidated Financial Results (Previous year: Disclaimer of Opinion)	
Qualification as reported in the Consolidated Auditor's Report	Management's Views / Response
(c) Qualification where impact is QUANTIFIED by the Auditor:	
<p>(c-i) Inventory Valuation – Difference between Book Value and Revalued Value:</p> <p>The inventory revaluation exercise was carried out on 18th December 2025 by the Resolution Professional (RP) during the Corporate Insolvency Resolution Process (CIRP). Based on such exercise, the value of inventory was determined at INR 603.10 lakhs as against the carrying value of INR 1,956.90 lakhs reflected in the books of account, resulting in a difference of INR 1,353.73 lakhs. The said valuation and related financial information were prepared and submitted by the Resolution Professional. Accordingly, such difference has a material impact on the valuation of closing inventory and cost of goods sold. In the absence of sufficient appropriate audit evidence to support the inventory value recorded by the management, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements.</p>	<p>Management's Response:</p> <p>The Resolution Professional has devalued the inventory by Rs. 1,353.73 lakhs upon the restatement of the non-moving, slow moving & damaged items at Net Realisable Value/ Scrap Value and has incorporated the same in the handling over financials to the implementation committee formed under the NCLT order for implementing resolution plan.</p> <p>The current management is in the process of incorporating the devaluation as above in the inventory module of the ERP Software, considering the large number of line items in the inventory, it is taking considerable time. Further the management is also evaluating the updated ERP Software for deployment.</p> <p>The management is of the view that the inventories are valued at cost or net realisable value, whichever is lower, in accordance with applicable Accounting Standards.</p>



II. Audit Qualifications – Details and Management Response (Consolidated)	
Quantified Impact: ↑ Expenditure / Cost of Goods Sold by Rs. 1,353.73 lakhs; ↓ Inventory (Total Assets) by Rs. 1,353.73 lakhs; ↓ Net Worth by Rs. 1,353.73 lakhs.	
(d) Qualifications where impact is NOT QUANTIFIED by the Auditor:	
(d)(i) Management's estimation on the impact of audit qualifications: Nil – Management is unable to estimate the financial impact at this stage for the following qualifications.	
(d)(ii) If Management is unable to estimate the impact, reasons for the same:	
Matters pertaining to the Holding Company – Cian Healthcare Limited:	
<p>(d-i) Trade Receivables, Advances and Deposits – Balance Confirmations Not Received:</p> <p>The balances of trade receivables, advances to others, and deposits paid are subject to confirmation. Due to the non-availability of balance confirmations from the respective parties, we were unable to obtain sufficient appropriate audit evidence regarding the accuracy and completeness of such balances. Consequently, we are unable to determine the consequential impact, if any, on the accompanying consolidated financial statements for the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>The current management (SRA) has taken over the affairs of the company on 1st February 2026 and is in the process of seeking balance confirmations of Receivables/ Advance from Customers/ Suppliers and adjustment if any would be booked. The management is of the opinion that it would not have significant difference in the carrying value of the same. Provisions has already been made for the doubtful assets, the adjustments, if any, would not have a material impact on the profitability of the company.</p>
<p>(d-ii) Property, Plant and Equipment and Capital Work-in-Progress – Physical Verification Not Obtained:</p> <p>In respect of the carrying value of Property, Plant and Equipment and Capital Work-in-Progress as on 31st March 2026, we were unable to obtain the physical verification report and related supporting documents. Consequently, in the absence of sufficient and appropriate audit evidence, we are unable to comment on the carrying value of such assets and the consequential impact, if any, on the accompanying consolidated financial statements.</p>	<p>Management's Response:</p> <p>For the purposes of handing over a true and fair statement of affairs of the Company to the SRA, the RP conducted a comprehensive physical verification and evaluation of the non-current and current assets of the company was undertaken after the NCLT order the same has been shared with the Auditors.</p> <p>The current management is in the process of implementing a system of physical verification, commensurate with the size of the company, in compliance with the provisions of Companies Act 2013.</p>
<p>(d-iii) GST Balance – Reconciliation Not Provided:</p> <p>The amount of ₹347.28 lakhs has been written off by the management and disclosed under Exceptional Gain/Loss on the ground that the corresponding input tax credit was not available on the GST portal.</p>	<p>Management's Response:</p> <p>Write –off of Rs 347.28 lakhs has been done by the RP which was also recorded in the handing over financials to the Implementation committee.</p>



II. Audit Qualifications – Details and Management Response (Consolidated)

However, proper GST reconciliation and supporting documentation in respect of the same have not been provided for our verification. Accordingly, we are unable to comment on the GST balances reported in the accompanying consolidated financial statements.

Regarding the differences in the current period which are mainly because of timing differences in return filing, Goods in Transit etc. There is a time gap in recording of GST purchases as all material received at the plant is accepted and purchase recorded after QC. Some continuing vendors are yet to record the NCLT mandated haircut in their books which is creating the reconciliation difference.

(d-iv) Foreign Exchange Gain/Loss – Incorrect Computation Methodology:

The Foreign Exchange Gain/Loss has not been computed on a transaction-wise basis as generally required under the applicable accounting framework; instead, the computation has been performed only on the basis of year-end closing balances. Such methodology is not in accordance with generally accepted accounting principles. In the absence of transaction-wise computation and supporting reconciliations, we are unable to comment on the correctness and completeness of the Foreign Exchange Gain/Loss reported in the consolidated financial statements.

Management's Response:

We acknowledge that the Foreign Exchange Gain/Loss for the year ended 31st March 2026 has been computed on the basis of the closing balance rather than on a transaction-wise basis as required under AS-11 (Effects of Changes in Foreign Exchange Rates) and generally accepted accounting principle.

We represent that the deviation from the transaction-wise computation methodology was due to limitations of the current accounting software, non-availability of complete transaction-level data and the accounting practices followed by the erstwhile management. The current management is evaluating the updated ERP Software for deployment to avoid such deviations in the future.

We are in the process of reconciliation of

(a) re-computing Foreign Exchange Gain/Loss on a transaction-wise basis,

(b) correcting prior year balances as applicable, and

(c) implement appropriate controls and data management practices for the correct computation of Foreign Exchange Gain/Loss going forward in the coming subsequent reporting period.


(d-v) Expected Credit Loss (ECL) Provision – Basis Not Supported:

During the course of our audit, we observed that the Company has recognised an Expected Credit Loss (ECL) provision amounting to INR 2,780.81 lakhs in respect of long outstanding loans and advances, trade receivables/debtors, and advances given to suppliers. However, we have not been provided with sufficient and appropriate audit evidence supporting the basis and methodology adopted for determination of such provision, including ageing analysis, recovery

Management's Response:

For the purposes of handing over a true and fair statement of affairs of the Company to the SRA, the RP conducted a comprehensive physical verification and evaluation of the non-current and current assets of the company was undertaken after the NCLT order the same has been shared with the Auditors.


The note regarding the same has been included in the handing over notes by the RP, which have been shared with the auditor.



II. Audit Qualifications – Details and Management Response (Consolidated)	
assessment, supporting correspondence, and management evaluation of recoverability.	The management is of the opinion that it would not have significant difference in the carrying value of the same. Provisions has already been made for the doubtful assets, the adjustments would not have a material impact on the future profitability of the company.
<p>(d-vi) Internal Financial Controls Over Financial Reporting – Not Made Available:</p> <p>The system of Internal Financial Controls over financial reporting was not made available to us to determine whether the Company has established adequate internal financial controls over financial reporting and whether such internal financial controls were operating effectively during the year ended 31st March 2026.</p>	<p>Management's Response:</p> <p>The current management is in the process of evaluation of the IFC Structure borrowed by the erstwhile management and establishing adequate internal financial controls over financial reporting to ensure the operating effectiveness of internal financial controls commensurate to the size of the company.</p> <p>Further, the management is also evaluating the updated ERP Software for deployment to avoid such deviations in the future.</p>
<p>(d-vii) Audit Trail – Unable to Verify:</p> <p>The Company has represented that it maintains an audit trail as required under the applicable provisions of the Companies Act, 2013. However, we were unable to independently verify the integrity, completeness, and effectiveness of the audit trail for the year under review. Accordingly, we are unable to comment on the adequacy and operating effectiveness of the audit trail maintained by the Company.</p>	<p>Management's Response:</p> <p>The ERP Software in use has the facility of maintaining audit logs and edit trail, the same was shown to the audit team during the course of the audit. Further, the management is also evaluating the updated ERP Software for deployment to avoid such deviations in the future.</p>
Matters pertaining to the Subsidiary – Dr. Smith's Biotech Private Limited:	
<p>(d-viii) Investment in Subsidiary – Dr. Smiths Biotech Private Limited (CIRP in Progress – Disclaimer of Opinion):</p> <p>Section 129(3) of the Companies Act, 2013 mandates that companies with subsidiaries must prepare consolidated financial statements. We draw attention to Note 8 of the accompanying consolidated financial results, which describes the circumstances relating to the investment of ₹708.84 lakhs made by the Company in its subsidiary, Dr. Smith's Biotech Private Limited. The Hon'ble NCLT, Mumbai Bench admitted an Insolvency and Bankruptcy petition filed by a financial creditor against Dr. Smith's Biotech Private Limited ("the Subsidiary") vide its Order dated 28th April 2025, ordering the commencement of CIRP. Megha Agrawal (IBBI/PA-001/IP-P-01456/2018-2019/12272) has been appointed as the Interim Resolution Professional / Resolution Professional.</p> <p>The financial statements of the Subsidiary for the year ended 31st March 2026 have been audited by</p>	<p>Management's Response:</p> <p>Share Premium of Rs. 488.84 lakhs, relating to investment in subsidiary company has been written off and the investment of Rs. 220.00 lakhs being its face value has been provided for by the RP as the company is under CIRP process. The final accounting treatment would be done after the NCLT pronounces its order on Dr. Smith. However, since the investment has been fully provided for, there would be no impact on the profitability of the company.</p> <p>The facts have already been disclosed in Note 8 of notes to accounts.</p>



II. Audit Qualifications – Details and Management Response (Consolidated)	
<p>another auditor, who have issued a Disclaimer of Opinion. The said audit report has been furnished to us and relied upon for the purpose of consolidation. Our conclusion on the consolidated Statement, in so far as it relates to the amounts and disclosures of the Subsidiary, is based solely on the report of the Subsidiary's auditor.</p> <p>As the CIRP proceedings of the subsidiary are currently in progress, out of the total investment of INR 708.84 lakhs in the subsidiary as at 31st March 2026, the Company has created a provision amounting to INR 220.00 lakhs. Further the balance amount of INR 488.84 lakhs, representing securities premium, has been written off through Exceptional Gain/Loss in the Balance Sheet. The eventual impact, if any, arising from the CIRP proceedings of the subsidiary will be accounted for as and when the outcome becomes ascertainable.</p> <p>Frequency of Qualification: During the year, Disclaimer of Opinion issued by subsidiary's auditor.</p>	
<p>(d-ix) Subsidiary's Financial Results – Dr. Smith's Biotech Private Limited (As at 31st March 2026):</p> <p>The consolidated financial results for the year ended 31st March 2026 include the financial results of Dr. Smith's Biotech Private Limited, whose financial statements were audited by another auditor. As per those financial statements:</p> <p>Total Assets: Rs.1,682.40 Lakhs as at 31st March 2026</p> <p>Total Liabilities: Rs.2,669.39 Lakhs as at 31st March 2026</p> <p>Net Worth: Rs. (987.00) Lakhs as at 31st March 2026</p> <p>Total Revenue: Rs. 1.03 Lakhs for the year ended 31st March 2026</p> <p>The subsidiary's auditor issued a Disclaimer of Opinion primarily on account of the following:</p> <p>(a) Going Concern – Material Uncertainty: The Subsidiary has halted operations since August 2024 due to financial distress and is undergoing CIRP. In the absence of a concrete resolution plan and with operations ceased, there exists significant uncertainty regarding the Subsidiary's ability to continue as a going concern. During the year, a successful investor was selected and has deposited a performance guarantee with the lenders.</p> <p>(b) Fixed Assets – Physical Verification Not Conducted: No physical verification reports, supporting documentation or reconciliation with books were made available. The auditor was unable to comment on the existence, physical condition and</p>	<p>Management's Response:</p> <p>Dr Smith Biotech Pvt Ltd was admitted into Corporate Insolvency Resolution Process (CIRP) by the Hon'ble National Company Law Tribunal (NCLT) with effect from 28 April 2026. Pursuant to the NCLT order, the management and control of the affairs of the subsidiary are vested with the Resolution Professional (RP). Accordingly, the Company has assessed that it no longer exercises control over the subsidiary from the said date for the purpose of preparation of financial statements. Consequently, the financial information considered in respect of the subsidiary has been based on the financial statements/information provided by the RP.</p>



II. Audit Qualifications – Details and Management Response (Consolidated)

valuation of fixed assets carrying a book value of ₹9,82,99,977 as at 31st March 2026, or any potential adjustments/impairments required.

(c) Inventory – No Physical Count: In the absence of a physical inventory counting report or independent verification records as at year-end, the auditor was unable to comment on the existence, condition and valuation of inventories valued at ₹45.46 Lakhs

(d) Trade Receivables and Trade Payables – No Confirmations: No direct balance confirmations or independent reconciliations were provided for Trade Receivables amounting to ₹415.99 Lakhs and Trade Payables/Creditors amounting to ₹1,014.21 Lakhs. Further, no provisioning or write-offs have been considered for potentially doubtful debts pending finalisation of the Resolution Plan.

(e) Statutory Dues – Default in Payment: The Subsidiary has defaulted in the timely deposition and payment of undisputed statutory dues, including GST, TDS, PF and ESIC, with the appropriate authorities.

(f) GST Input Tax Credit – Unreconciled Difference: ITC balance in books of accounts: ₹103.64 Lakhs; ITC balance per GST portal: ₹22.34 Lakhs; Unreconciled difference: ₹81.3 Lakhs. In the absence of reconciliations and adequate explanations, the auditor was unable to comment on the correctness of the ITC balance in the books.

(g) Audit Trail – Not Verifiable: Management did not provide details about audit trail logs maintained. The auditor was unable to comment on whether the audit trail (edit log) facility was in operation throughout the year, whether it was tampered with, or whether records were retained for the prescribed period.

In the absence of adequate reconciliations, balance confirmations, supporting documents and alternative audit procedures, the auditor was unable to determine the impact of adjustments, impairments, provisions or write-offs, if any, required in the financial statements as at 31st March 2026.

Frequency of Qualification: Disclaimer of Opinion issued by subsidiary's another auditor.



ii. Audit Qualifications - Details and Management Response (Consolidated)

(d)(iii) Auditor's comment on (i) and (ii) above: Auditor's comments are self-explanatory as stated in the Consolidated Auditor's Report issued for the half-year and year ended 31st March 2026. The Subsidiary's auditor's comments are as stated in the audit report issued by another auditor.

<p>For and on behalf of the Board of Directors Clan Healthcare Limited CIN: L24233PN2003PLC017583</p> <p><i>Rajesh Jain</i></p> <p>Rajesh Jain Managing Director DIN: 02066848</p> <p>Date: 30/05/2026 Place: Pune</p>	<p>Statutory Auditors For S S R C A & Co. Chartered Accountants (Formerly known as S S Rathi & Co.) Firm Registration No. 108726W</p> <p><i>Hemant Samdani</i></p> <p>CA Hemant Samdani Partner Membership No. 155955 UDIN: <u>26155955VYDWLU7844</u></p> <p>Date: 30/05/2026 Place: Pune</p> 
<p>For and on behalf of the Audit Committee Chairman Clan Healthcare Limited CIN: L24233PN2003PLC017583</p> <p><i>मनीष गोस्वामी</i></p> <p>Manish Goswami Director DIN: 05301935</p> <p>Date: 30/05/2026 Place: Pune</p>	<p>For and on behalf of the Clan Healthcare Limited CIN: L24233PN2003PLC017583</p> <p><i>Kalyani</i></p> <p>Kalyani Vijay Chordia CFO</p> <p>Date: 30/05/2026 Place: Pune</p>

